Home › MannKind Co. (MNKD) Upgraded to "Buy" at Zacks Investment Research
 

Keywords :   


MannKind Co. (MNKD) Upgraded to "Buy" at Zacks Investment Research

2016-01-16 23:09:46| Biotech - Topix.net

The brokerage presently has a $1.00 target price on the biopharmaceutical company's stock. Zacks Investment Research 's price objective indicates a potential upside of 7.71% from the company's current price.

Tags: buy research investment upgraded

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
02.11Eastern North Pacific Tropical Weather Outlook
02.11Atlantic Tropical Weather Outlook
01.11Tropical Depression Thirteen-E Forecast Discussion Number 1
01.11Tropical Depression Thirteen-E Graphics
01.11Tropical Depression Thirteen-E Wind Speed Probabilities Number 1
01.11Summary for Tropical Depression Thirteen-E (EP3/EP132024)
01.11Eastern North Pacific Tropical Weather Outlook
01.11Atlantic Tropical Weather Outlook
More »